SRPT
Sarepta Therapeutics Inc
18.70$
+1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 11.2% | 11.1% | 12.2% | 12.3% | 19.6% | 20.1% | 18.5% | 25.0% | 37.8% | 90.0% | 16.3% | 37.2% | 41.4% | |
| 88.8% | 88.9% | 87.8% | 87.7% | 80.4% | 79.9% | 81.5% | 75.0% | 62.2% | 10.0% | 83.7% | 62.8% | 58.6% | |
| 58.6% | 49.3% | 48.5% | 49.5% | 48.1% | 30.4% | 103.8% | 33.4% | 54.8% | 73.5% | 21.1% | 22.7% | 40.0% | |
| 36.4% | 33.2% | 30.7% | 38.2% | 27.4% | 24.9% | 17.9% | 22.6% | 23.0% | 29.0% | 14.9% | 26.8% | 22.1% | |
| 95.1% | 82.7% | 79.3% | 87.9% | 75.6% | 55.3% | 121.9% | 56.1% | 88.1% | 102.9% | 34.6% | 59.5% | 65.8% | |
| -6.3% | 6.2% | 8.4% | -0.2% | 4.8% | 24.6% | -40.3% | 18.9% | -25.9% | -92.9% | 49.0% | 3.3% | -7.3% | |
| 1.6% | 1.3% | 1.0% | 1.3% | 1.1% | 0.7% | 0.6% | 0.9% | 1.9% | 1.7% | 3.0% | 5.4% | 3.0% | |
| -10.0% | 10.2% | 10.0% | 3.7% | 7.3% | 26.1% | -51.5% | 25.1% | -48.6% | -62.8% | 47.0% | -0.4% | -6.6% | |
| 2.3% | -1.3% | 1.3% | 2.0% | 0.1% | 1.9% | 8.6% | -7.1% | -3.5% | 1.0% | 1.7% | 0.8% | 0.3% | |
| -12.3% | 11.5% | 8.7% | 1.8% | 7.2% | 24.2% | -60.1% | 32.2% | -45.1% | -63.9% | 45.3% | -1.2% | -6.9% | |
| -5.1% | 14.4% | 13.1% | 7.5% | 10.4% | 28.4% | -49.5% | 27.8% | -42.1% | -56.9% | 51.4% | 7.5% | -0.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.